Citigroup Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $20
Citigroup analyst Yigal Nochomovitz initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $20.
Biomea Fusion Doses First Patient In Phase I/Ib Clinical Trial Of BMF-219 In KRAS Mutant Solid Tumors
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)
A pan-KRAS inhibitor
Analyst Expectations for Biomea Fusion’s Future
Biomea Fusion (NASDAQ:BMEA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…
US Stocks Edge Lower; Bank of America Profit Tops Views
U.S. stocks traded lower this morning, with the Dow Jones dropping around 50 points on Friday.
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $37 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Biomea Fusion (NASDAQ:BMEA) with a Buy and maintains $37 price target.
Biomea Fusion Q3 EPS $(0.78) Down From $(0.43) YoY
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.78) per share. This is a 81.4 percent decrease over losses of $(0.43) per share from the same period last year.
Biomea Fusion To Present Preclinical Data For BMF-500, An Investigational Oral Covalent FLT3 Inhibitor, At The 64th American Society Of Hematology Annual Meeting
BMF-500, an investigational third generation covalent FLT3 inhibitor, has demonstrated preclinically that it may be the most potent and selective inhibitor of FLT3 evaluated to date:
Greater Cytotoxicity: In acute
EF Hutton Initiates Coverage On Biomea Fusion with Buy Rating, Announces Price Target of $27
EF Hutton analyst Michael King initiates coverage on Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $27.
HC Wainwright & Co. Maintains Buy on Biomea Fusion, Raises Price Target to $37
HC Wainwright & Co. analyst Joseph Pantginis maintains Biomea Fusion (NASDAQ:BMEA) with a Buy and raises the price target from $16 to $37.
BMF-219 Enters the Clinic For KRAS Solid Tumor; Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent Menin Inhibitor BMF-219 In KRAS Solid Tumors
Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors.
Biomea Fusion will now initiate a Phase I/Ib clinical trial